Added benefit of Afatinib depends on mutation status in non-small cell lung cancer

Lung cancer patients with Del19 mutation benefit mostAfatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/-zdGhpAhL9Y/272932.php

rehab sport sport medical